Therapeutic Strategies to Treat Dry Eye in an Aging Population

Nisreen S. Ezuddin, Karam A. Alawa, Anat Galor

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

Dry eye (DE) is a prevalent ocular disease that primarily affects the elderly. Affecting up to 30 % of adults aged 50 years and older, DE affects both visual function and quality of life. Symptoms of DE, including ocular pain (aching, burning), visual disturbances, and tearing, can be addressed with therapeutic agents that target dysfunction of the meibomian glands, lacrimal glands, goblet cells, ocular surface, and/or neural network. This review provides an overview of the efficacy, use, and limitations of current therapeutic interventions being used to treat DE.

Original languageEnglish (US)
Pages (from-to)505-513
Number of pages9
JournalDrugs and Aging
Volume32
Issue number7
DOIs
StatePublished - Jul 29 2015

Fingerprint

Population
Eye Pain
Meibomian Glands
Therapeutics
Lacrimal Apparatus
Goblet Cells
Eye Diseases
Quality of Life

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Geriatrics and Gerontology

Cite this

Therapeutic Strategies to Treat Dry Eye in an Aging Population. / Ezuddin, Nisreen S.; Alawa, Karam A.; Galor, Anat.

In: Drugs and Aging, Vol. 32, No. 7, 29.07.2015, p. 505-513.

Research output: Contribution to journalArticle

Ezuddin, Nisreen S. ; Alawa, Karam A. ; Galor, Anat. / Therapeutic Strategies to Treat Dry Eye in an Aging Population. In: Drugs and Aging. 2015 ; Vol. 32, No. 7. pp. 505-513.
@article{faafd8b50ea943a7b96d8100e0427a31,
title = "Therapeutic Strategies to Treat Dry Eye in an Aging Population",
abstract = "Dry eye (DE) is a prevalent ocular disease that primarily affects the elderly. Affecting up to 30 {\%} of adults aged 50 years and older, DE affects both visual function and quality of life. Symptoms of DE, including ocular pain (aching, burning), visual disturbances, and tearing, can be addressed with therapeutic agents that target dysfunction of the meibomian glands, lacrimal glands, goblet cells, ocular surface, and/or neural network. This review provides an overview of the efficacy, use, and limitations of current therapeutic interventions being used to treat DE.",
author = "Ezuddin, {Nisreen S.} and Alawa, {Karam A.} and Anat Galor",
year = "2015",
month = "7",
day = "29",
doi = "10.1007/s40266-015-0277-6",
language = "English (US)",
volume = "32",
pages = "505--513",
journal = "Drugs and Aging",
issn = "1170-229X",
publisher = "Adis International Ltd",
number = "7",

}

TY - JOUR

T1 - Therapeutic Strategies to Treat Dry Eye in an Aging Population

AU - Ezuddin, Nisreen S.

AU - Alawa, Karam A.

AU - Galor, Anat

PY - 2015/7/29

Y1 - 2015/7/29

N2 - Dry eye (DE) is a prevalent ocular disease that primarily affects the elderly. Affecting up to 30 % of adults aged 50 years and older, DE affects both visual function and quality of life. Symptoms of DE, including ocular pain (aching, burning), visual disturbances, and tearing, can be addressed with therapeutic agents that target dysfunction of the meibomian glands, lacrimal glands, goblet cells, ocular surface, and/or neural network. This review provides an overview of the efficacy, use, and limitations of current therapeutic interventions being used to treat DE.

AB - Dry eye (DE) is a prevalent ocular disease that primarily affects the elderly. Affecting up to 30 % of adults aged 50 years and older, DE affects both visual function and quality of life. Symptoms of DE, including ocular pain (aching, burning), visual disturbances, and tearing, can be addressed with therapeutic agents that target dysfunction of the meibomian glands, lacrimal glands, goblet cells, ocular surface, and/or neural network. This review provides an overview of the efficacy, use, and limitations of current therapeutic interventions being used to treat DE.

UR - http://www.scopus.com/inward/record.url?scp=84938418333&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84938418333&partnerID=8YFLogxK

U2 - 10.1007/s40266-015-0277-6

DO - 10.1007/s40266-015-0277-6

M3 - Article

C2 - 26123947

AN - SCOPUS:84938418333

VL - 32

SP - 505

EP - 513

JO - Drugs and Aging

JF - Drugs and Aging

SN - 1170-229X

IS - 7

ER -